| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Endogenous metabolite; galactokinase (GALK); galactose-1-phosphate uridylyltransferase (GALT); UDP-galactose-4-epimerase (GALE); Leloir pathway enzymes. D-Galactose is phosphorylated by galactokinase to galactose-1-phosphate, which is converted to UDP-galactose and then to UDP-glucose. It also contributes to glycoprotein and glycolipid synthesis.
|
|---|---|
| ln Vitro |
Drug compounds have been modified to include stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to impact a drug's pharmacokinetic and metabolic characteristics, deuteration has drawn attention[1].
In vitro, D-Galactose-d1 is used for metabolic flux analysis in cultured cells. It is taken up by cells and metabolized via the Leloir pathway. The d1 label enables quantification of galactose conversion to glucose and incorporation into glycoproteins. At high concentrations (10-100 mM), it induces oxidative stress and cellular senescence in vitro. |
| ln Vivo |
In vivo, D-Galactose-d1 is used for metabolic tracing in animal models. Chronic administration of D-galactose (100-200 mg/kg/day) induces accelerated aging and oxidative stress in rodents. The d1 label enables quantification of galactose-derived metabolites in blood and tissues, and tracing of glycoprotein synthesis in liver and brain.
|
| Enzyme Assay |
For Leloir pathway enzyme assays, galactokinase is incubated with D-Galactose-d1 (0.1-10 mM) and ATP. Galactose-1-phosphate formation is measured by coupled enzyme assay. GALT activity is measured by UDP-glucose consumption. GALE activity is measured by UDP-galactose conversion to UDP-glucose. Products are analyzed by HPLC or LC-MS/MS.
|
| Cell Assay |
For metabolic labeling, cells are cultured in medium containing D-Galactose-d1 (1-25 mM) for 24-72 hours. Metabolites are extracted and analyzed by LC-MS/MS to quantify d1 enrichment in galactose-1-phosphate, UDP-galactose, UDP-glucose, and glycoproteins. For senescence studies, cells are treated with high D-galactose (50-200 mM) for 1-2 weeks, and senescence markers are assessed.
|
| Animal Protocol |
For in vivo metabolic tracing, mice receive D-Galactose-d1 (100-500 mg/kg) via oral gavage or intraperitoneal injection. Blood and tissues are collected at defined time points (0-24 hours). Metabolites are extracted and analyzed by LC-MS/MS. For aging studies, rodents receive D-galactose (100-200 mg/kg/day) for 6-8 weeks, and oxidative stress markers and cognitive function are assessed.
|
| References |
| Molecular Formula |
C6H11DO6
|
|---|---|
| Molecular Weight |
181.16
|
| Exact Mass |
181.07
|
| CAS # |
64429-86-3
|
| Related CAS # |
D-Galactose; 59-23-4; D-Galactose-13C; 70849-30-8; D-Galactose-13C-2; 478518-56-8; D-Galactose-13C6; 74134-89-7; D-Galactose-d2-1; 1176791-08-4; D-Galactose-13C,d; 370565-96-1; D-Galactose-13C-3; 478518-58-0; D-Galactose-13C-4; 478518-60-4; D-Galactose-13C-5; 478518-62-6; D-Galactose-d; 64267-73-8; D-Galactose-d-2; 478518-70-6; D-Galactose-d-3; 478518-71-7; D-Galactose-d2; 35669-34-2
|
| PubChem CID |
12285873
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.6
|
| tPSA |
110.38
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1C([C@]([2H])([C@H]([C@H]([C@H]1CO)O)O)O)O
|
| InChi Key |
WQZGKKKJIJFFOK-ODFFSVOISA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1/i5D
|
| Chemical Name |
(3R,4S,5R,6R)-3-deuterio-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5200 mL | 27.5999 mL | 55.1998 mL | |
| 5 mM | 1.1040 mL | 5.5200 mL | 11.0400 mL | |
| 10 mM | 0.5520 mL | 2.7600 mL | 5.5200 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.